Flavonoids show promise in treating type 2 diabetes mellitus by targeting the enteroendocrine system and regulating key gut ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Also known as type 1.5 diabetes, here’s what to know about the onset, symptoms, diagnosis, and treatment options for latent ...

Alongside this research, other studies have shown that lifestyle choices can also help manage diabetes. Eating more whole ...

Exposure to antibiotics during a key developmental window in infancy can stunt the growth of insulin-producing cells in the ...

Type 1 and type 2 diabetes require different approaches. Discover the 9 essential distinctions that affect daily management ...

Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the ...

Exposure to antibiotics during a key developmental window in infancy can stunt growth of insulin-producing cells in the pancreas and may boost risk of diabetes later in life, new research in mice ...

BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will ...

People who develop type 2 diabetes face an increased risk of some of the most lethal cancers, including liver and pancreatic ...

Irene Wells didn't ask just how bad her pancreatic cancer was — she just wanted aggressive treatment so she could do "a ...